Подход drip and ship в сравнении с непосредственным направлением в специализированный центр по лечению инсульта. Моделирование условной вероятности


Дж.К. Холодински, Т.С. Виллиамсон, Н. Камал, Д. Маиянк, ­ М.Д. Хилл, М. Гойял

Department of Community Health Sciences, Alberta Children’s Hospital Research Institute and O’Brien Institute for Public Health, Departments of Clinical Neurosciences and Radiology, Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada; and Division of Engineering Science, University of Toronto, Ontario, Canada.

Литература


  1. Menon B.K., Sajobi T.T., Zhang Y., Rempel J.L., Shuaib A., Thornton J., et al.­ Analysis of workflow and time to treatment on thrombectomy outcome in the endovascular treatment for small core and proximal occlusion ischemic stroke (ESCAPE) randomized, controlled trial. Circulation. 2016;133:2279–2286. doi: 10.1161/CIRCULATIONAHA.115.019983.
  2. Saver J.L. Time is brain–quantified. Stroke. 2006;37:263–266. ­doi: 10.1161/01.STR.0000196957.55928.ab.
  3. Saver J.L., Goyal M., Bonafe A., Diener H.C., Levy E.I., Pereira V.M., et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–2295. doi: 10.1056/NEJMoa1415061.
  4. Jovin T.G., Chamorro A., Cobo E., de Miquel M.A., Molina C.A., Rovira A., et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–2306. doi: 10.1056/NEJMoa1503780.
  5. Berkhemer O.A., Fransen P.S., Beumer D., van den Berg L.A., Lingsma H.F., Yoo A.J., et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20. ­doi: 10.1056/NEJMoa1411587.
  6. Campbell B.C., Mitchell P.J., Kleinig T.J., Dewey H.M., Churilov L., Yassi N., et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–1018. doi: 10.1056/NEJMoa1414792.
  7. Goyal M., Demchuk A.M., Menon B.K., Eesa M., Rempel J.L., Thornton J., et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–1030. doi: 10.1056/NEJMoa1414905.
  8. Powers W.J., Derdeyn C.P., Biller J., Coffey C.S., Hoh B.L., Jauch E.C., ­et al; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020–3035. doi: 10.1161/STR.0000000000000074.
  9. Ouriel K., Welch E.L., Shortell C.K., Geary K., Fiore W.M., Cimino C. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. J Vasc Surg. 1995;22:593–597.
  10. Viguier A., Petit R., Rigal M., Cintas P., Larrue V. Continuous monitoring of middle cerebral artery recanalization with transcranial color-coded sonography and Levovist. J Thromb Thrombolysis. 2005;19:55–59. doi:10.1007/s11239-005-0940-6.
  11. Muchada M., Rodriguez-Luna D., Pagola J., Flores A., Sanjuan E., Meler P., et al. Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2014;45:2734–2738. doi: 10.1161/STROKEAHA.114.006222.
  12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587. doi: 10.1056/NEJM199512143332401.
  13. Goyal M., Jadhav A.P., Bonafe A., Diener H., Mendes Pereira V., Levy E., et al; SWIFT PRIME investigators. Analysis of workflow and time ­to treatment and the effects on outcome in endovascular treatment of acute ischemic stroke: results from the SWIFT PRIME randomized controlled trial. Radiology. 2016;279:888–897. doi: 10.1148/radiol.2016160204.
  14. Mishra S.M., Dykeman J., Sajobi T.T., Trivedi A., Almekhlafi M., Sohn S.I., et al. Early reperfusion rates with IV tPA are determined by CTA clot characteristics. AJNR Am J Neuroradiol. 2014;35:2265–2272. ­doi: 10.3174/ajnr.A4048.
  15. Nazliel B., Starkman S., Liebeskind D.S., Ovbiagele B., Kim D., Sanossian N., et al. A brief prehospital stroke severity scale identifies ischemic stroke patients harboring persisting large arterial occlusions. Stroke. 2008;39:2264–2267. doi: 10.1161/STROKEAHA.107.508127.
  16. Parsons M., Spratt N., Bivard A., Campbell B., Chung K., Miteff F., et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–1107. doi: 10.1056/NEJMoa1109842.
  17. Goyal M., Yu A.Y., Menon B.K., Dippel D.W., Hacke W., Davis S.M., et al. Endovascular therapy in acute ischemic stroke: challenges and transition from trials to bedside. Stroke. 2016;47:548–553. doi: 10.1161/STROKEAHA.115.011426.
  18. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137. doi: 10.1056/NEJMoa0707534.
  19. Mendelow A.D., Gregson B.A., Rowan E.N., Murray G.D., Gholkar A., Mitchell P.M.; STICH II Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013;382:397–408. doi: 10.1016/S0140-6736(13)60986-1.
  20. Anderson C.S., Heeley E., Huang Y., Wang J., Stapf C., Delcourt C., et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355–2365. doi: 10.1056/NEJMoa1214609.
  21. Fonarow G.C., Zhao X., Smith E.E., Saver J.L., Reeves M.J., Bhatt D.L., ­et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311:1632–1640. doi: 10.1001/jama.2014.3203.
  22. Fonarow G.C., Smith E.E., Saver J.L., Reeves M.J., Bhatt D.L., Grau-Sepulveda M.V., et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750–758. doi: 10.1161/CIRCULATIONAHA.110.974675.
  23. Higashida R., Alberts M.J., Alexander D.N., Crocco T.J., Demaerschalk B.M., Derdeyn C.P., et al; American Heart Association Advocacy Coordinating Committee. Interactions within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association. Stroke. 2013;44:2961–2984. doi: 10.1161/STR.0b013e3182a6d2b2.
  24. Hill M.D., Goyal M., Demchuk A.M., Fisher M. Ischemic stroke tissuewindow in the new era of endovascular treatment. Stroke. 2015;46:2332–2334. doi: 10.1161/STROKEAHA.115.009688.
  25. Ebinger M., Winter B., Wendt M., Weber J.E., Waldschmidt C., Rozanski M., et al; STEMO Consortium. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: ­a randomized clinical trial. JAMA. 2014;311:1622–1631. doi: 10.1001/jama.2014.2850.
  26. Walter S., Kostopoulos P., Haass A., Keller I., Lesmeister M., Schlechtriemen T., et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11:397–404. doi: 10.1016/S1474-4422(12)70057-1.
  27. Rajan S.S., Rajan S., Baraniuk S., Parker S., Wu T.C., Bowry R., et al. Implementing a mobile stroke unit program in the United States: why, how, and how much? JAMA Neurol. 2015;72:229–234. doi: 10.1001/jamaneurol.2014.3618.


Похожие статьи


Бионика Медиа